Wendy’s rejects $1.4 billion Trian buyout offer, adopts poison pill defense

Wendy's rejected a $1.4B takeover offer from Trian Fund Management and others at $7.35 per share, citing undervaluation. The board supports CEO Bob Wright's turnaround plan, 'Dave's Way,' and adopted a poison pill to prevent hostile takeovers. Shares fell less than 1% in morning trading, according to CNBC.

Wendy's rejected an unsolicited takeover bid and announced a $200M breakfast exit plan. Q3 2026 results showed weak sales but sequential improvements. U.S. same-restaurant sales fell 5.7%, total revenue was $435.6M. CEO Bob Wright cited early signs of progress but no formal guidance was provided.

Wendy's (WEN) rejected a buyout offer from an investor group, focusing instead on its turnaround strategy. The company aims to improve operations and financial performance.

Wendy's reported a 5.7% drop in U.S. same-store sales for Q3, its seventh consecutive quarterly decline. The company rejected a $1.4B buyout offer, citing undervaluation. Adjusted EPS beat estimates at $0.13, while revenue fell 0.5% to $547M. Wendy's is implementing a multi-year turnaround plan, 'Dave's Way,' focusing on menu improvements and store closures. Franchisee struggles and breakfast menu changes are also part of the strategy.

Wendy's rejected a $7.35 per share takeover offer from Trian and allies, calling it undervalued. The board adopted a poison pill to deter a hostile takeover. Q3 same-store sales fell, but earnings and revenue beat estimates. Shares dipped 1% in premarket trading.

Wendy's rejected a $1.4 billion buyout offer, calling it too low. The company adopted a 'poison pill' strategy to prevent a hostile takeover. Wendy's believes the bid undervalues its long-term potential under new leadership.